Cash burn and runway

Hong Kong IPO disclosure precedents · 136 companies, 136 items

cash burn rate and how many months existing cash will last (typically Chapter 18A / 18C, loss-making issuers)

2024-10-23Prospectus
Beijing Biostar Pharmaceuticals Co., Ltd.北京华昊中天生物医药股份有限公司02563.HK

Assuming an average cash burn rate going forward of 1.2 times of the level for the five months ended May 31, 2024, we estimate that our cash and cash equivalents, fixed deposits with banks and financial assets measured at fair value through profit or loss as of August 31, 2024, totaling RMB476.4 million, will be able to maintain our financial viability for approximately 34 months taking into account the estimated net proceeds from the Global Offering (based on the low-end of the indicative Offer Price range).

Financial Information · p. 477

Our Directors will continue to monitor our working capital, cash flows and our business development progress.

Financial Information · p. 477
The company's explanation, the adviser's view and the page in the filing: see Matters
2024-09-27Prospectus
Zhejiang Taimei Medical Technology Co., Ltd.浙江太美医疗科技股份有限公司02576.HK

Our Directors are of the opinion that we will have adequate working capital and sufficient cash balance to support our business growth until we achieve a net operating cash inflow position, without taking account of the estimated proceeds from the Global Offering, on the following grounds:

Financial Information · p. 418

(i) we had cash and cash equivalents of RMB698.9 million, short-term bank deposits of RMB13.5 million and short-term investments measured at fair value through profit or loss of RMB264.3 million, which are all highly liquid assets, as of March 31, 2024.

Financial Information · p. 418

Having taken into account the factors above and the independent due diligence work conducted by the Joint Sponsors, nothing has come to the Joint Sponsors’ attention that would reasonably cause them to cast doubt on the reasonableness of the Directors’ view that the Group has sufficient working capital to meet its present requirements and for at least the next 12 months from the date of this prospectus in any material aspects.

Financial Information · p. 418
The company's explanation, the adviser's view and the page in the filing: see Matters
2024-08-12Prospectus
TYK Medicines, Inc浙江同源康医药股份有限公司02410.HK

Assuming an average cash burn rate going forward of 1.2 times the level in the Track Record Period, we estimate that our cash and cash equivalents financial assets measured at FVTPL as of March 31, 2024 will be able to maintain our financial viability for over 22.0 months from March 31, 2024, without taking into account 7.0% of the estimated net proceeds from the Global Offering, namely, the portion allocated for our working capital and other general corporate purposes; or, we estimate we will be able to maintain our financial viability for over 23.1 months from March 31, 2024, if we take into account 7.0% of the estimated net proceeds from the Global Offering.

Financial Information · p. 491

Our Directors are of the opinion that, taking into account the financial resources available to us, including cash and cash equivalents and the estimated net proceeds from the Global Offering, and considering our cash burn rate, we have available sufficient working capital to cover at least 125% of our costs, including general, administrative and operating costs (including any production costs), research and development costs, and business development and marketing expenses, for at least the next 12 months from the date of this prospectus.

Financial Information · p. 491
The company's explanation, the adviser's view and the page in the filing: see Matters
2024-07-31Prospectus
Black Sesame International Holding Limited黑芝麻智能国际控股有限公司02533.HK

Our historical cash burn rate was RMB56.6 million, RMB70.1 million, RMB100.8 million, RMB107.4 million and RMB105.1 million in 2021, 2022, 2023 and the three months ended March 31, 2023 and 2024, respectively, mainly representing our investment in R&D activities.

Financial Information · p. 405

We had cash and cash equivalents, current financial assets at fair value through profit or loss and unutilized banking facilities of RMB1,370.5 million as of May 31, 2024.

Financial Information · p. 405

we estimate that our cash and cash equivalents, current financial assets at fair value through profit or loss and unutilized banking facilities as of May 31, 2024 will be able to maintain our financial viability for 15.6 months or, if we take into account 10% of the estimated net proceeds from the Listing (namely, the portion allocated for our working capital and other general corporate purposes), 16.6 months or, if we also take into account the estimated net proceeds from the Listing, 25.8 months.

Financial Information · p. 405
The company's explanation, the adviser's view and the page in the filing: see Matters
2024-06-04Prospectus

Our historical monthly average cash burn rate was RMB37.1 million, RMB53.0 million and RMB62.2 million in 2021, 2022 and 2023, respectively.

Financial Information · p. 597

we estimate that our cash and cash equivalents, current portion of term deposits, current portion of financial assets at FVTPL and restricted cash as of December 31, 2023 will be able to maintain our financial viability for approximately 45.5 months or, if we take into account 10% of the estimated net proceeds from the Global Offering (namely, the portion allocated for our working capital and other general purposes), approximately 46.9 months or, if we take into account 100% of the estimated net proceeds (based on the mid-point of the indicative Offer Price) from the Global Offering, for approximately 59.3 months.

Financial Information · p. 597
The company's explanation, the adviser's view and the page in the filing: see Matters
2024-05-16Prospectus
Sunho Biologics, Inc.盛禾生物控股有限公司02898.HK

Assuming an average cash burn rate going forward of 6.3 times the level in 2023, taking into account the scheduled payment of indebtedness, we estimate that our cash at bank and on hand, together with other financial assets and time deposits as of December 31, 2023 will be able to maintain our financial viability for 9 months, or, if we also take into account the estimated net proceeds (based on the Offer Price of HK$13.50 per Share), 30 months.

Financial Information · p. 443

Our Directors are of the opinion that, taking into account the financial resources available to our Group, including cash and cash equivalents and the estimated net proceeds from the Global Offering, we have available sufficient working capital to cover at least 125% of the Group’s costs, including general, administrative and operating costs (including any production costs), research and development costs for at least the next 12 months from the date of this prospectus.

Financial Information · p. 443
The company's explanation, the adviser's view and the page in the filing: see Matters
2024-03-12Prospectus
Qyuns Therapeutics Co., Ltd.江苏荃信生物医药股份有限公司02509.HK

Taking into account our cash and cash equivalents and short-maturity financial products we purchased, and assuming average monthly net cash used in operating activities and capital expenditures going forward of 1.5 times the average level in 2021 and 2022, we estimate we will be able to maintain our financial viability for 12.9 months from the date of this prospectus without considering proceeds from the Global Offering; or, if we also take into account the net proceeds from Global Offering, assuming an Offer Price of HK$19.80 per Offer Share (being the low-end of the indicative Offer Price range), 18.5 months from the date of this prospectus.

Financial Information · p. 498

Taking into account of the above, together with the estimated net proceeds from this Global Offering, the Directors are of the opinion that we have sufficient working capital to cover at least 125% of our costs, including general, administrative and operating costs and research and development costs, for at least the next 12 months from the date of this prospectus.

Financial Information · p. 498
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-12-14Prospectus
HighTide Therapeutics, Inc.君圣泰医药02511.HK

Our Directors are of the opinion that, taking into account the financial resources available to us, including cash and cash equivalents and the estimated net proceeds from the Global Offering, and considering our cash burn rate, we have sufficient working capital to cover at least 125% of our costs, including research and development expenses and administrative expenses for at least the next 12 months from the date of this prospectus.

Financial Information · p. 421

Assuming an average cash burn rate going forward of 2.1 times the level in 2022, we estimate that our total cash balance as of June 30, 2023, will be able to maintain our financial viability for approximately 25 months or, if taking into account the estimated net proceeds from the Global Offering, for at least 31 months.

Financial Information · p. 421
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-09-13Prospectus
WUHAN YZY BIOPHARMA CO., LTD.武汉友芝友生物制药股份有限公司02496.HK

Our Directors are of the opinion that, taking into account the financial resources available, including cash and cash equivalents of RMB12.6 million as of July 31, 2023, financial assets at FVTPL, unutilized bank facilities and the estimated net proceeds from the Global Offering, as well as our cash burn rate, we have sufficient working capital to cover at least 125% of our costs, including research and development expenses, administrative expenses and other operating expenses for at least the next 12 months from the date of this prospectus.

Financial Information · p. 523

We had cash and cash equivalents of RMB12.6 million as of July 31, 2023.

Financial Information · p. 523

Our Directors and management team will continue to monitor our working capital, cash flows and our business development progress.

Financial Information · p. 524
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-08-24Prospectus
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.宜明昂科生物医药技术(上海)股份有限公司01541.HK

Our Directors believe that, by taking into account our cash and cash equivalents of RMB559.1 million as of April 30, 2023 and assuming that our cash burn rate going forward will be approximately 1.1 times of the cash burn rate for the year ended December 31, 2022, we can remain financially viable for approximately 34 months from April 30, 2023 if taking into account the estimated net proceeds from the Global Offering (being the indicative Offer Price of HK$18.60 per H Share).

Financial Information · p. 397

we have sufficient working capital to cover at least 125% of our costs, including research and development costs, general, administrative and operating costs, for at least the next 12 months from the date of this prospectus.

Financial Information · p. 396
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-06-29Prospectus
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.四川科伦博泰生物医药股份有限公司06990.HK

Assuming an average cash burn rate going forward of 1.0 times the level in the years ended December 31, 2021 and 2022, we estimate that our cash and cash equivalents as of April 30, 2023 will be able to maintain our financial viability for over 36 months from April 30, 2023, without taking into account 5.0% of the estimated net proceeds from the Global Offering (namely, the portion allocated for our working capital and other general corporate purposes);

Financial Information · p. 530

As of April 30, 2023, the latest practicable date for determining our indebtedness, we had cash and cash equivalents of RMB1,342.2 million.

Financial Information · p. 527
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-06-16Prospectus
Laekna, Inc.来凯医药有限公司02105.HK

we estimate that our cash and cash equivalents as of December 31, 2022 for the purpose of the indebtedness statement, will be able to maintain our financial viability for approximately 8.4 months or, if taking into account the estimated net proceeds (based on the Offer Price of HK$12.41 per Offer Share) from the Global Offering, for at least 25.7 months.

Financial Information · p. 411

Our Directors are of the opinion that, taking into account the financial resources available to us, including cash and cash equivalents and the estimated net proceeds from the Global Offering, and considering our cash burn rate, we have sufficient working capital to cover at least 125% of our costs, including research and development expenses and administrative expenses for at least the next 12 months from the expected date of this prospectus.

Financial Information · p. 411
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-05-31Prospectus
Cutia Therapeutics科笛集团02487.HK

Assuming an average cash burn rate going forward of 2.0 times the level in 2022, we estimate that our cash at bank and on hand as of December 31, 2022 will be able to maintain our financial viability for 39 months taking into account the estimated net proceeds from the Global Offering and for 17 months without taking into account the estimated net proceeds from the Global Offering.

Financial Information · p. 424

We will continue to monitor our cash flows from operations closely and expect to raise our next round of financing, if needed, with a minimum buffer of 12 months.

Financial Information · p. 424
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-04-25Prospectus
Beijing Luzhu Biotechnology Co., Ltd.北京绿竹生物技术股份有限公司02480.HK

Taking into consideration the higher-than-before research and development expenses after LZ901 proceeded to its Phase III clinical trial in China and its Phase I clinical trials in the U.S., and assuming an average cash burn rate going forward of approximately 1.4 times the level for the 12 months ended December 31, 2022, we estimate that our cash and cash equivalents and financial assets at FVTPL, which were redeemable on demand as of February 28, 2023, or had been redeemed as of the date of this prospectus, and the proceeds received from bank facilities as of the date of this prospectus will be able to maintain our financial viability for approximately 14.5 months or, if we also take into account the estimated net proceeds (based on the low-end of the indicative Offer Price) from the Global Offering, for approximately 19.9 months.

Financial Information · p. 394

We will continue to monitor our working capital closely and expect to raise our next round of financing, if needed, with a minimum buffer of twelve months.

Financial Information · p. 394
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-03-30Prospectus
Beisen Holding Limited北森控股有限公司09669.HK

Furthermore, we had total cash and cash equivalents, financial assets at fair value through profit or loss (short-term), term deposits (short-term), and restricted cash (short-term) of RMB1,584.3 million as of September 30, 2022.

Summary · p. 17

Based on the average historical monthly cash burn rate across the six months ended September 30, 2022, the total of RMB1,584.3 million cash sources will be able to support the our operations for over 43 months from September 30, 2022 till April 30, 2026, without taking into account the estimated net proceeds from the Global Offering and future net cash inflow.

Summary · p. 18

In addition, it is estimated that additional working capital of approximately RMB200 million to RMB300 million may be required before our current net operating cash outflow position is turned into a net operating cash inflow position, which we currently expect to happen in 2025, based on information currently available to us.

Summary · p. 17
The company's explanation, the adviser's view and the page in the filing: see Matters
2023-03-16Prospectus
DPC Dash Ltd达势股份有限公司01405.HK

For the years ended December 31, 2021 and 2022, we had a positive net cash inflow from our operating activities (the net cash generated from operating activities less lease-related cash outflow from financing activities (cash outflow from payment of the principal and interest elements of lease liabilities)) of RMB136.4 million and RMB77.1 million respectively, which were primarily driven by revenue growth and enhanced store-level profitability during the period as we continued to expand our store network.

Financial Information · p. 352

The abovementioned analysis is for illustrative purposes only and our Directors estimate that the likelihood of such a situation occurring is extremely remote.

Financial Information · p. 353
The company's explanation, the adviser's view and the page in the filing: see Matters

Tell us